{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T20:36:21Z","timestamp":1787776581281,"version":"build-2784847793"},"reference-count":34,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2025,2,1]]},"abstract":"Importance<\/jats:title>Sporadic Creutzfeldt-Jakob disease (sCJD) is a rare, rapidly progressive and fatal neurodegenerative disease. Definite sCJD diagnosis can only be made post mortem, and little is known about the prodromal phase of the disease.<\/jats:p><\/jats:sec>Objective<\/jats:title>To compare drug prescription patterns before the clinical onset of sCJD between patients and matched controls for exploration of potential risk factors and to assess correlations between drug exposure and sCJD survival.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This retrospective analysis was designed as a case-control study, with data collected from January 2013 to December 2020 and analyzed in 2023. Follow-up was available until December 2020. Cases were collected from the Austrian Reference Centre for Human Prion Diseases, which receives all suspected cases at a national level in Austria. The analyses were conducted at a single center. Patients with autopsy-confirmed sCJD were linked with insurance claims data, and a minimum of 10 control individuals were matched by sex, age at onset, and area of residence for each patient with sCJD.<\/jats:p><\/jats:sec>Exposure<\/jats:title>Medication prescribed to 10% or more of the cohort with sCJD up to 5 years before symptom onset or the matching date in the control cohort.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Drug prescription before symptom onset or the matching date was compared between patients with sCJD and controls using conditional regression, and prescriptions in the cohort with sCJD were assessed for correlation with survival using Cox proportional hazard models.<\/jats:p><\/jats:sec>Results<\/jats:title>A total of 129 patients with sCJD (median [IQR] age, 68.9 [62.4-75.5] years; 67 female [51.9%]) and 1350 controls (median [IQR] age, 69.0 [62.2-75.3] years; 700 female [51.9%]) were included. As compared with controls, patients with sCJD were found to have significantly higher odds of being prescribed selective serotonin reuptake inhibitors (SSRIs) in the year preceding disease onset (odds ratio, 2.86; 95% CI, 1.63-4.95; P<\/jats:italic>\u2009&amp;lt;\u2009.001). SSRI prescription rates started to increase 3 years before symptom onset in the cohort with sCJD.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>Results of this case-control study provide evidence for prodromal mood alterations as early as 3 years before symptom onset in patients with sCJD. Although sCJD remains an extremely rare cause of mood alterations, increased vigilance for neurodegenerative diseases in this setting could eventually help to extend the diagnostic window.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaneurol.2024.4447","type":"journal-article","created":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T16:31:48Z","timestamp":1735576308000},"page":"185","source":"Crossref","is-referenced-by-count":6,"title":["Mood Alterations in the Prodromal Phase of Sporadic Creutzfeldt-Jakob Disease"],"prefix":"10.1001","volume":"82","author":[{"given":"Raphael","family":"Wurm","sequence":"first","affiliation":[{"name":"Department of Neurology, Medical University of Vienna, Vienna, Austria"},{"name":"Comprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigrid","family":"Klotz","sequence":"additional","affiliation":[{"name":"Comprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna, Vienna, Austria"},{"name":"Division of Neuropathology and Neurochemistry, Department of Neurology, Medical University of Vienna, Vienna, Austria"},{"name":"Austrian Reference Center for Human Prion Diseases, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Erber","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Center for Public Health, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Gruber","sequence":"additional","affiliation":[{"name":"Main Association of Austrian Social Security Institutions, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Leitner","sequence":"additional","affiliation":[{"name":"Main Association of Austrian Social Security Institutions, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berthold","family":"Reichardt","sequence":"additional","affiliation":[{"name":"Austrian Social Health Insurance Fund, \u00d6sterreichische Gesundheitskasse, Eisenstadt, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"St\u00f6gmann","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical University of Vienna, Vienna, Austria"},{"name":"Comprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Schernhammer","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Center for Public Health, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Gelpi","sequence":"additional","affiliation":[{"name":"Comprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna, Vienna, Austria"},{"name":"Division of Neuropathology and Neurochemistry, Department of Neurology, Medical University of Vienna, Vienna, Austria"},{"name":"Austrian Reference Center for Human Prion Diseases, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakan","family":"Cetin","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical University of Vienna, Vienna, Austria"},{"name":"Comprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"noi240080r1","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.1016\/S1473-3099(19)30615-2","article-title":"Creutzfeldt-Jakob disease: a systematic review of global incidence, prevalence, infectivity, and incubation.","volume":"20","author":"Uttley","year":"2020","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"noi240080r2","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.3233\/JAD-180123","article-title":"Unusual clinical presentations challenging the early clinical diagnosis of Creutzfeldt-Jakob disease.","volume":"64","author":"Baiardi","year":"2018","journal-title":"J Alzheimers Dis"},{"issue":"8","key":"noi240080r3","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1002\/pds.1630","article-title":"Association between serious ischemic cardiac outcomes and medications used to treat diabetes.","volume":"17","author":"Margolis","year":"2008","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"noi240080r4","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s13311-018-0611-x","article-title":"Anti-herpetic medications and reduced risk of dementia in patients with herpes simplex virus infections\u2014a nationwide, population-based cohort study in Taiwan.","volume":"15","author":"Tzeng","year":"2018","journal-title":"Neurotherapeutics"},{"issue":"4","key":"noi240080r5","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1001\/jamaneurol.2015.4791","article-title":"Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis.","volume":"73","author":"Gomm","year":"2016","journal-title":"JAMA Neurol"},{"issue":"2","key":"noi240080r6","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1016\/j.sapharm.2021.06.016","article-title":"A narrative review of using prescription drug databases for comorbidity adjustment: a less effective remedy or a prescription for improved model fit?","volume":"18","author":"Barnett","year":"2022","journal-title":"Res Social Adm Pharm"},{"issue":"4","key":"noi240080r7","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1111\/ene.15675","article-title":"Analysis of comedication in people with dementia.","volume":"30","author":"Wurm","year":"2023","journal-title":"Eur J Neurol"},{"issue":"16","key":"noi240080r8","doi-asserted-by":"publisher","first-page":"10849","DOI":"10.1073\/pnas.162195499","article-title":"Tetracyclines affect prion infectivity.","volume":"99","author":"Forloni","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"noi240080r9","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1097\/01.LAB.0000074919.08232.A2","article-title":"Differential inhibition of prion propagation by enantiomers of quinacrine.","volume":"83","author":"Ryou","year":"2003","journal-title":"Lab Invest"},{"issue":"2","key":"noi240080r10","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1136\/jnnp-2016-313541","article-title":"Doxycycline in early CJD: a double-blinded randomised phase 2 and observational study.","volume":"88","author":"Varges","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"noi240080r11","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/S1474-4422(13)70307-7","article-title":"Doxycycline in Creutzfeldt-Jakob disease: a phase 2, randomized, double-blind, placebo-controlled trial.","volume":"13","author":"Ha\u00efk","year":"2014","journal-title":"Lancet Neurol"},{"issue":"1","key":"noi240080r12","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s40478-022-01415-7","article-title":"Sporadic Creutzfeldt-Jakob disease VM1: phenotypic and molecular characterization of a novel subtype of human prion disease.","volume":"10","author":"Gelpi","year":"2022","journal-title":"Acta Neuropathol Commun"},{"issue":"4","key":"noi240080r13","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s00401-012-1002-8","article-title":"Consensus classification of human prion disease histotypes allows reliable identification of molecular subtypes: an inter-rater study among surveillance centers in Europe and USA.","volume":"124","author":"Parchi","year":"2012","journal-title":"Acta Neuropathol"},{"issue":"158","key":"noi240080r14","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1080\/01621459.1927.10502953","article-title":"Probable inference, the law of succession, and statistical inference.","volume":"22","author":"Wilson","year":"1927","journal-title":"J Am Stat Assoc"},{"issue":"Pt 9","key":"noi240080r15","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1093\/brain\/awl159","article-title":"Determinants of diagnostic investigation sensitivities across the clinical spectrum of sporadic Creutzfeldt-Jakob disease.","volume":"129","author":"Collins","year":"2006","journal-title":"Brain"},{"issue":"1","key":"noi240080r16","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing.","volume":"57","author":"Benjamini","year":"1995","journal-title":"J R Stat Soc B"},{"issue":"17","key":"noi240080r17","doi-asserted-by":"publisher","first-page":"9836","DOI":"10.1073\/pnas.161274798","article-title":"Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease.","volume":"98","author":"Korth","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"noi240080r18","doi-asserted-by":"publisher","first-page":"e331","DOI":"10.1212\/WNL.0000000000005860","article-title":"Validation and utilization of amended diagnostic criteria in Creutzfeldt-Jakob disease surveillance.","volume":"91","author":"Hermann","year":"2018","journal-title":"Neurology"},{"issue":"2","key":"noi240080r19","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1212\/01.wnl.0000196440.00297.67","article-title":"First symptom in sporadic Creutzfeldt-Jakob disease.","volume":"66","author":"Rabinovici","year":"2006","journal-title":"Neurology"},{"issue":"3","key":"noi240080r20","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1007\/s00415-014-7615-1","article-title":"Familial Creutzfeldt-Jakob disease with the E200K mutation: longitudinal neuroimaging from asymptomatic to symptomatic CJD.","volume":"262","author":"Cohen","year":"2015","journal-title":"J Neurol"},{"issue":"1","key":"noi240080r21","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1002\/mds.24051","article-title":"Toward a redefinition of Parkinson disease.","volume":"27","author":"Stern","year":"2012","journal-title":"Mov Disord"},{"issue":"7","key":"noi240080r22","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.jalz.2019.04.001","article-title":"Duration of preclinical, prodromal, and dementia stages of Alzheimer disease in relation to age, sex, and APOE genotype.","volume":"15","author":"Vermunt","year":"2019","journal-title":"Alzheimers Dement"},{"issue":"1","key":"noi240080r23","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/brain\/awab404","article-title":"Preventing amyotrophic lateral sclerosis: insights from presymptomatic neurodegenerative diseases.","volume":"145","author":"Benatar","year":"2022","journal-title":"Brain"},{"issue":"1-2","key":"noi240080r24","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1159\/000479696","article-title":"Epidemiology of multiple sclerosis in Austria.","volume":"49","author":"Salhofer-Polanyi","year":"2017","journal-title":"Neuroepidemiology"},{"issue":"1","key":"noi240080r25","doi-asserted-by":"publisher","first-page":"3298","DOI":"10.1038\/s41467-019-10914-6","article-title":"Country-wide medical records infer increased allergy risk of gastric acid inhibition.","volume":"10","author":"Jordakieva","year":"2019","journal-title":"Nat Commun"},{"issue":"7","key":"noi240080r26","doi-asserted-by":"publisher","first-page":"329","DOI":"10.5414\/CP203410","article-title":"The role of general practitioners and psychiatrists in issuing initiation and follow-up prescriptions for selective serotonin (norepinephrine) reuptake inhibitors in Germany.","volume":"57","author":"Kap","year":"2019","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"4","key":"noi240080r27","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s00406-021-01368-3","article-title":"The sociodemographic and clinical profile of patients with major depressive disorder receiving SSRIs as first-line antidepressant treatment in European countries.","volume":"272","author":"Fugger","year":"2022","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"23","key":"noi240080r28","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1212\/WNL.0b013e3182a9f3b4","article-title":"Quinacrine treatment trial for sporadic Creutzfeldt-Jakob disease.","volume":"81","author":"Geschwind","year":"2013","journal-title":"Neurology"},{"issue":"3","key":"noi240080r29","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a024430","article-title":"Insights from therapeutic studies for PrP prion disease.","volume":"7","author":"Teruya","year":"2017","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"1","key":"noi240080r30","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jalz.2016.07.005","article-title":"The DIAN-TU Next Generation Alzheimer\u2019s prevention trial: adaptive design and disease progression model.","volume":"13","author":"Bateman","year":"2017","journal-title":"Alzheimers Dement"},{"issue":"1","key":"noi240080r31","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.46319","article-title":"Validation of revised International Creutzfeldt-Jakob Disease Surveillance Network diagnostic criteria for sporadic Creutzfeldt-Jakob disease.","volume":"5","author":"Watson","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"8","key":"noi240080r32","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1111\/ene.14252","article-title":"Increased risk of death associated with the use of proton pump inhibitors in patients with dementia and controls\u2014a pharmacoepidemiological claims data analysis.","volume":"27","author":"Cetin","year":"2020","journal-title":"Eur J Neurol"},{"issue":"9","key":"noi240080r33","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1002\/pds.1454","article-title":"Using prescription claims data for drugs available over the counter (OTC).","volume":"16","author":"Yood","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"noi240080r34","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1159\/000126915","article-title":"Creutzfeldt-Jakob disease in Austria: an autopsy-controlled study.","volume":"30","author":"Gelpi","year":"2008","journal-title":"Neuroepidemiology"}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/articlepdf\/2828525\/jamaneurology_wurm_2024_oi_240080_1738707025.77773.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T16:01:59Z","timestamp":1739203319000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2828525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,1]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2024.4447","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2,1]]}}}